Objective  To explore the relationship between p53 codon 72 gene polymorphism and the risk of breast cancer in Chinese women. 

Methods  Relevant literature published in PubMed, Embase, Web of Science, CNKI and WanFang Database was searched systematically from inception to March 31, 2021. Two reviewers independently screened the literature, extracted data, and evaluated the risk of bias in the included studies. The systematic review and meta-analysis were performed using Review Manager version 5.4 and Stata version 16.0. 

Results  A total of 13 studies were included in this me-ta-analysis, including 5,411 breast cancer patients and 5,758 non-tumor or healthy subjects. Total me-ta-analysis results showed that the homozygous model [PP vs. RR: OR=1.16, 95%CI(0.93, 1.46), P=0.200], the recessive model [PP vs. RR+PR: OR=1.09, 95%CI(0.91, 1.32), P=0.340] and the dominant model [PP+PR vs. RR: OR=1.13, 95%CI(0.97, 1.30), P=0.120] suggested that codon 72 gene polymor-phism may not be associated with the risk of breast cancer in Chinese women; but the heterozygous analysis model [PR vs. RR: OR=1.15, 95%CI(1.05, 1.26), P=0.002] suggests that polymorphism may be associated with the risk of breast cancer in Chinese women. Subgroup analysis further found that stud-ies with larger sample sizes made it easier to conclude that the p53 codon 72 gene polymorphism was related to the risk of breast cancer in Chinese women. In addition, in the heterozygous model, when the control group represented a healthy community or the genotype frequency met the Hardy-Weinberg balance, it was easy to draw similar conclusions that the p53 codon 72 gene polymorphism was related to the risk of breast cancer in Chinese women. Both the funnel plot and Egger's test showed no publica-tion bias. Sensitivity analysis showed that, except for the dominant model, all other model analyses suggested that a single study did not change the results of the meta-analysis. 

Conclusion  Heterozy-gous model analysis suggests that p53 codon 72 gene polymorphisms may be associated with the risk of breast cancer in Chinese women. In the future, more high-quality and large sample studies are needed for verification.

1.Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1): 7-30. DOI: 10.3322/caac.21590.

2.Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in China: a second-ary analysis of the global cancer statistics 2020[J]. Chin Med J (Engl), 2021, 134(7): 783-791. DOI: 10.1097/CM9.0000000000001474.

3.龚珂, 肖钧方, 刘香婷, 等. 乳腺癌易感基因相关研究现状[J]. 现代肿瘤医学, 2020, 28(23): 4184-4190. [Gong K, Xiao JF, Liu XT, et al. Research status of breast cancer susceptibility genes[J]. Journal of Modern On-cology, 2020, 28(23): 4184-4190.] DOI: 10.3969/j.issn.1672-4992. 2020.23.035.

4.Hainaut P, Plymoth A. Targeting the hallmarks of cancer:  towards a rational approach to next-generation cancer therapy[J]. Curr Opin Oncol, 2013, 25(1): 50-51. DOI: 10.1097/CCO.0b013e32835b651e.

5.Silwal-Pandit L, Vollan HK, Chin SF, et al. TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance[J]. Clin Cancer Res, 2014, 20(13): 3569-3580. DOI: 10.1158/1078-0432.CCR-13-2943.

6.Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field[J]. Nat Rev Can-cer, 2009, 9(10): 701-713. DOI: 10.1038/nrc2693.

7.Silwal-Pandit L, Langerød A, Børresen-Dale AL. TP53 Mutations in breast and ovarian cancer[J]. Cold Spring Harb Perspect Med, 2017, 7(1): a026252. DOI: 10.1101/cshperspect.a026252.

8.Bisof V, Salihović MP, Narancić NS, et al. TP53 gene polymorphisms and breast cancer in Croatian women: a pilot study[J]. Eur J Gynaecol Oncol, 2010, 31(5): 539-544. DOI: 10.1016/j.earlhumdev.2009.12.002. 

9.Cavallone L, Arcand SL, Maugard C, et al. Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent[J]. BMC Cancer, 2008, 8: 96. DOI: 10.1186/1471-2407-8-96.

10.Costa S, Pinto D, Pereira D, et al. Importance of TP53 codon 72 and intron 3 duplication 16bp poly-morphisms in prediction of susceptibility on breast cancer[J]. BMC Cancer, 2008, 8: 32. DOI: 10.1186/1471-2407-8-32.

11.De Vecchi G, Verderio P, Pizzamiglio S, et al. The p53 Arg72Pro and Ins16bp polymorphisms and their haplotypes are not associated with breast cancer risk in BRCA-mutation negative familial cases[J]. Cancer Detect Prev, 2008, 32(2): 140-143. DOI: 10.1016/j.cdp.2008.06.003.

12.Pim D, Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progres-sion[J]. Int J Cancer, 2004, 108(2): 196-199. DOI: 10.1002/ijc.11548.

13.Saadatian Z, Gharesouran J, Ghojazadeh M, et al. Association of rs1219648 in FGFR2 and rs1042522 in TP53 with premenopausal breast cancer in an Iranian Azeri population[J]. Asian Pac J Cancer Prev, 2014, 15(18): 7955-7958. DOI: 10.7314/apjcp.2014.15.18.7955.

14.Syeed N, Sameer AS, Abdullah S, et al. A case-control study of TP53 R72P polymorphism in the breast cancer patients of ethnic Kashmiri population[J]. World J Oncol, 2010, 1(6): 236-241. DOI: 10.4021/wjon261w.

15.Zhang Z, Wang M, Wu D, et al. P53 codon 72 polymorphism contributes to breast cancer risk: a me-ta-analysis based on 39 case-control studies[J]. Breast Cancer Res Treat, 2010, 120(2): 509-517. DOI: 10.1007/s10549-009-0480-4.

16.Gonçalves ML, Borja SM, Cordeiro JA, et al. Association of the TP53 codon 72 polymorphism and breast cancer risk: a meta-analysis[J]. Springerplus, 2014, 3: 749. DOI: 10.1186/2193-1801-3-749.

17.Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test[J]. BMJ, 1997, 315(7109): 629-634. DOI: 10.1136/bmj.315.7109.629.

18.Hao WM, Xu X, Shi HF, et al. No association of TP53 codon 72 and intron 3 16-bp duplication poly-morphisms with breast cancer risk in Chinese Han women: new evidence from a population-based case-control investigation[J]. Eur J Med Res, 2018, 23(1): 47. DOI: 10.1186/s40001-018-0345-6.

19.Leu JD, Wang CY, Tsai HY, et al. Involvement of p53 R72P polymorphism in the association of MDM2-SNP309 with breast cancer[J]. Oncol Rep, 2011, 25(6): 1755-1763. DOI: 10.3892/or.2011.1254.

20.Liu JB, Tang XH, Li M, et al. Functional MDM4 rs4245739 genetic variant, alone and in combination with P53 Arg72Pro polymorphism, contributes to breast cancer susceptibility[J]. Breast Cancer Res Treat, 2013, 140(1): 151-157. DOI: 10.1007/s10549-013-2615-x.

21.Li T, Lu ZM, Guo M, et al. p53 codon 72 polymorphism (C/G) and the risk of human papilloma-virus-associated carcinomas in China[J]. Cancer, 2002, 95(12): 2571-2576. DOI: 10.1002/cncr.11008.

22.Chen FY, Wang H, Li H, et al. Association of single-nucleotide polymorphisms in monoubiquitinated FANCD2-DNA damage repair pathway genes with breast cancer in the Chinese population[J]. Technol Cancer Res Treat, 2018, 17: 1533033818819841. DOI: 10.1177/153303 3818819841.

23.Ma H, Hu Z, Zhai X, et al. Joint effects of single nucleotide polymorphisms in P53BP1 and p53 on breast cancer risk in a Chinese population[J]. Carcinogenesis, 2006, 27(4): 766-771. DOI: 10.1093/carcin/bgi295.

24.Siddique MM, Balram C, Fiszer-Maliszewska L, et al. Evidence for selective expression of the p53 co-don 72 polymorphs: implications in cancer development[J]. Cancer Epidemiol Biomarkers Prev, 2005, 14(9): 2245-2252. DOI: 10.1158/1055-9965.EPI-05-0153.

25.Lum SS, Chua HW, Li H, et al. MDM2 SNP309 G allele increases risk but the T allele is associated with earlier onset age of sporadic breast cancers in the Chinese population[J]. Carcinogenesis, 2008, 29(4): 754-761. DOI: 10.1093/carcin/bgn024.

26.Song F, Zheng H, Liu B, et al. An miR-502-binding site single-nucleotide polymorphism in the 3'-untranslated region of the SET8 gene is associated with early age of breast cancer onset[J]. Clin Cancer Res, 2009, 15(19): 6292-6300. DOI: 10.1158/1078-0432.CCR-09-0826.

27.梁寒梅, 刘建萍, 王金霞. p53 codon 72多态性与乳腺癌风险性的关系[J]. 世界最新医学信息文摘（连续型电子期刊）, 2013, (3): 20-21. [Liang HM, Liu JP, Wang JX. Genetic polymorphisms of p53codon 72 and the risk of breast cancer[J]. World Latest Medicine Information, 2013, (3): 20-21.] DOI: 10.3969/j.issn. 1671-3141.2013.03.012.

28.南今娘,  陈春杰,  胡续光, 等. p53 codon 72多态性与延边地区乳腺癌发生的相关性[J]. 延边大学医学学报, 2010, 33(4): 243-246. [Nan JN, Chen CJ, Hu XG, et al. Study on correlation between p53 codon 72 polymor-phism and breast cancer in Yanbian area[J]. Journal of Medical Science Yanbian University, 2010, 33(4): 243-246.] DOI: 10.16068/j.1000-1824.2010.04.023.

29.王梅丽, 徐云霞, 钱健, 等. 鼠双微体-2基因多态及P53基因多态与乳腺癌易感性的关联研究[J]. 中华预防医学杂志, 2013, 47(2): 124-128. [Wang ML, Xu YX, Qian J, et al. Association of murine double minute 2 and P53 polymorphisms with breast cancer susceptibility[J]. Chinese Journal of Preventive Medicine, 2013, 47(2): 124-128.] DOI: 10.3760/cma.j.issn.0253-9624.2013.02.007.

30.张薇, 金明娟, 陈坤, 等. p53基因多态及单体型分布与乳腺癌危险性的关联研究[J]. 浙江大学学报（医学版）, 2007, 36(6): 561-566. [Zhang W, Jin MJ, Chen K. Association of p53 polymorphisms and its haplotypes with susceptibility of breast cancer[J]. Journal of Zhejiang University (Medical Sciences), 2007, 36(6): 561-566.] DOI: 10.1631/jzus.B1000196.

31.Hrstka R, Coates PJ, Vojtesek B. Polymorphisms in p53 and the p53 pathway: roles in cancer suscepti-bility and response to treatment[J]. J Cell Mol Med, 2009, 13(3): 440-453. DOI: 10.1111/j.1582-4934.2008.00634.x.

32.Pietsch EC, Humbey O, Murphy ME. Polymorphisms in the p53 pathway[J]. Oncogene, 2006, 25(11): 1602-1611. DOI: 10.1038/sj.onc.1209367.

33.Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications[J]. Nat Rev Cancer, 2009, 9(2): 95-107. DOI: 10.1038/nrc2584.

34.Breast Cancer Association Consortium. Commonly studied single-nucleotide polymorphisms and breast cancer: results from the Breast Cancer Association Consortium[J]. J Natl Cancer Inst, 2006, 98(19): 1382-1396. DOI: 10.1093/jnci/djj374.

35.Dastjerdi MN, Mansoor S, Mohajeri MR, et al. Evidence for an association of TP53 codon 72 poly-morphism with sporadic colorectal cancer risk in Isfahan[J]. J Res Med Sci, 2008, 13(6): 317-323. 

36.Sreeja L, Syamala V, Raveendran PB, et al. p53 Arg72Pro polymorphism predicts survival outcome in lung cancer patients in Indian population[J]. Cancer Invest, 2008, 26(1): 41-46. DOI: 10.1080/07357900701638459.

37.Dumont P, Leu JI, Della Pietra AC 3rd, et al. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential[J]. Nat Genet, 2003, 33(3): 357-365. DOI: 10.1038/ng1093.

38.Walker KK, Levine AJ. Identification of a novel p53 functional domain that is necessary for efficient growth suppression[J]. Proc Natl Acad Sci U S A, 1996, 93(26): 15335-15340. DOI: 10.1073/pnas.93.26.15335.

39.Grochola LF, Zeron-Medina J, Mériaux S, et al. Single-nucleotide polymorphisms in the p53 signaling pathway[J]. Cold Spring Harb Perspect Biol, 2010, 2(5): a001032. DOI: 10.1101/cshperspect.a001032.

40.聂伟伟, 管晓翔, 陈龙邦. p53 codon 72多态性在乳腺癌发生发展中的作用[J]. 癌症进展, 2011, 9(3): 295-297, 270. [Nie WW, Guan XX, Chen LB. The role of p53 codon 72 polymorphism in the occurrence and de-velopment of breast cancer[J]. Oncology Progress, 2011, 9(3): 295-297, 270.] DOI: 10.3969/j.issn.1672-1535.2011.03.016.